Xilio Therapeutics, Inc.
XLO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $19,066 | $8,084 | $2,930 | $1,724 |
| % Growth | 135.8% | 175.9% | 70% | – |
| Cost of Goods Sold | $340 | $15,330 | $0 | $0 |
| Gross Profit | $18,726 | -$7,246 | $2,930 | $1,724 |
| % Margin | 98.2% | -89.6% | 100% | 100% |
| R&D Expenses | $14,321 | $15,330 | $8,266 | $8,836 |
| G&A Expenses | $0 | $7,120 | $8,515 | $6,517 |
| SG&A Expenses | $6,334 | $7,120 | $8,515 | $6,517 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$15,330 | $0 | $0 |
| Operating Expenses | $20,655 | $7,120 | $16,781 | $15,353 |
| Operating Income | -$1,929 | -$14,366 | -$13,851 | -$13,629 |
| % Margin | -10.1% | -177.7% | -472.7% | -790.5% |
| Other Income/Exp. Net | -$14,358 | -$1,478 | $586 | $536 |
| Pre-Tax Income | -$16,287 | -$15,844 | -$13,265 | -$13,093 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16,287 | -$15,844 | -$13,265 | -$13,093 |
| % Margin | -85.4% | -196% | -452.7% | -759.5% |
| EPS | -0.11 | -0.16 | -0.18 | -0.2 |
| % Growth | 31.3% | 11.1% | 10% | – |
| EPS Diluted | -0.11 | -0.16 | -0.18 | -0.2 |
| Weighted Avg Shares Out | 144,107 | 96,448 | 74,700 | 64,676 |
| Weighted Avg Shares Out Dil | 144,107 | 96,448 | 74,700 | 64,676 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $340 | $381 | $497 | $375 |
| EBITDA | -$15,947 | -$13,985 | -$13,354 | -$13,254 |
| % Margin | -83.6% | -173% | -455.8% | -768.8% |